MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 625-631

  Ko, Ya Chen ^a   Fang, Woei Horng ^b,c   Lin, Tsung Chin ^b   Hou, Hsin An ^c   Chen, Chien Yuan ^c   Tien, Hwei Fang ^c   Lin, Liang In ^b,c  

^a YUANPEI UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; CCAAT enhancer binding protein ; DNA methylation; MiRNA let 7a 3

Indexed keywords

ACUTE MYELOID LEUKEMIA; CCAAT/ENHANCER BINDING PROTEIN Α; DNA METHYLATION; MIRNA LET-7A-3;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; MIDDLE AGED; PROMOTER REGIONS, GENETIC;

EID: 84899106437     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.03.008     Document Type: Article

References (42)

1. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., van Putten W.L., Valk P.J., Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113:3088-3091.
2. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
3. Hou H.A., Lin L.I., Chen C.Y., Tien H.F. Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'. Br J Cancer 2009, 101:738-740.
4. Grossmann V., Schnittger S., Kohlmann A., Eder C., Roller A., Dicker F., et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012, 120:2963-2972.
5. Tang J.L., Hou H.A., Chen C.Y., Liu C.Y., Chou W.C., Tseng M.H., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114:5352-5361.
6. Hou H.A., Kuo Y.Y., Liu C.Y., Chou W.C., Lee M.C., Chen C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119:559-568.
7. Hou H.A., Huang T.C., Lin L.I., Liu C.Y., Chen C.Y., Chou W.C., et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010, 115:5222-5231.
8. Lin T.C., Hou H.A., Chou W.C., Ou D.L., Yu S.L., Tien H.F., et al. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia 2011, 25:32-40.
9. Marcucci G., Mrozek K., Radmacher M.D., Garzon R., Bloomfield C.D. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011, 117:1121-1129.
10. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010, 79:351-379.
11. Huntzinger E., Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011, 12:99-110.
12. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J Pathol 2011, 223:102-115.
13. Garofalo M., Croce C.M. microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 2011, 51:25-43.
14. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
15. Lee Y.S., Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007, 21:1025-1030.
16. Johnson C.D., Esquela-Kerscher A., Stefani G., Byrom M., Kelnar K., Ovcharenko D., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67:7713-7722.
17. Dong Q., Meng P., Wang T., Qin W., Wang F., Yuan J., et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 2010, 5:e10147.
18. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
19. Sampson V.B., Rong N.H., Han J., Yang Q., Aris V., Soteropoulos P., et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007, 67:9762-9770.
20. Yu C.C., Chen Y.W., Chiou G.Y., Tsai L.L., Huang P.I., Chang C.Y., et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol 2011.
21. Schultz J., Lorenz P., Gross G., Ibrahim S., Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008, 18:549-557.
22. Nie K., Zhang T., Allawi H., Gomez M., Liu Y., Chadburn A., et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol 2010, 177:1470-1479.
23. Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007, 138:3-11.
24. Wouters B.J., Jorda M.A., Keeshan K., Louwers I., Erpelinck-Verschueren C.A., Tielemans D., et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007, 110:3706-3714.
25. Melki J.R., Vincent P.C., Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999, 59:3730-3740.
26. Brueckner B., Stresemann C., Kuner R., Mund C., Musch T., Meister M., et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007, 67:1419-1423.
27. Lu L., Katsaros D., de la Longrais I.A., Sochirca O., Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007, 67:10117-10122.
28. Lu L., Katsaros D., Zhu Y., Hoffman A., Luca S., Marion C.E., et al. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat 2011, 126:687-694.
29. Tien H.F., Wang C.H., Lin M.T., Lee F.Y., Liu M.C., Chuang S.M., et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995, 84:60-68.
30. Lin L.I., Chen C.Y., Lin D.T., Tsay W., Tang J.L., Yeh Y.C., et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005, 11:1372-1379.
31. Hou H.A., Chou W.C., Lin L.I., Chen C.Y., Tang J.L., Tseng M.H., et al. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia 2008, 22:1075-1078.
32. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006, 66:3310-3316.
33. Lin L.I., Lin T.C., Chou W.C., Tang J.L., Lin D.T., Tien H.F. A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia 2006, 20:1899-1903.
34. Lin T.C., Jiang S.S., Chou W.C., Hou H.A., Lin Y.M., Chang C.L., et al. Rapid assessment of the heterogeneous methylation status of CEBPA in patients with acute myeloid leukemia by using high-resolution melting profile. J Mol Diagn 2011, 13:514-519.
35. Vrba L., Munoz-Rodriguez J.L., Stampfer M.R., Futscher B.W. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One 2013, 8:e54398.
36. Pabst T., Mueller B.U., Zhang P., Radomska H.S., Narravula S., Schnittger S., et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
37. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
38. Garzon R., Pichiorri F., Palumbo T., Visentini M., Aqeilan R., Cimmino A., et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26:4148-4157.
39. Wang D.J., Legesse-Miller A., Johnson E.L., Coller H.A. Regulation of the let-7a-3 promoter by NF-kappaB. PLoS One 2012, 7:e31240.
40. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
41. Grunwald M.R., Levis M.J. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013, 97:683-694.
42. Li Y., Lin J., Yang J., Qian J., Qian W., Yao D.M., et al. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res 2013, 37:1642-1647.